BORTEZOMIB-CYCLOPHOSPHAMIDE-DEXAMETHASONE IS A GOOD INDUCTION TREATMENT FOR YOUNG PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

被引：0
|
作者：
Lakhwani, S. [1 ]
Notario, C. [2 ]
de Bonis, C. [1 ]
Brena, J. [2 ]
Raya, J. M. [1 ]
Sanchez-Quintana, A. [1 ]
Rios-Rull, P. [2 ]
Trujillo-Gonzalez, M. [2 ]
Hernandez, M. T. [1 ]
机构：
[1] Hosp Univ Canarias, Santa Cruz De Tenerife, Spain
[2] Hosp Univ Nuestra Senora de la Candelaria, Santa Cruz De Tenerife, Spain
来源：
HAEMATOLOGICA | 2014年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PB1706
引用
收藏
页码：657 / 657
页数：1
相关论文
共 50 条
  • [1] Induction Therapy with Bortezomib-Cyclophosphamide-Dexamethasone (BCD) for Newly Diagnosed Transplant Eligible Patients with Multiple Myeloma
    Tsukada, Nobuhiro
    Ikeda, Masahiro
    Shingaki, Sumito
    Miyazaki, Kanji
    Meshitsuka, Sosuke
    Abe, Yu
    Yoshiki, Yumiko
    Suzuki, Kenshi
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (02) : S205 - S205
  • [2] Bortezomib-Cyclophosphamide-Dexamethasone for Relapsing Multiple Myeloma
    Fu, Weijun
    Delasalle, Kay
    Wang, Jialei
    Song, Shen
    Hou, Jian
    Alexanian, Raymond
    Wang, Michael
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2012, 35 (06): : 562 - 565
  • [3] Bortezomib-cyclophosphamide-dexamethasone induction/consolidation and bortezomib maintenance for transplant-eligible newly diagnosed multiple myeloma: phase 2 multicenter trial
    Muranushi, Hiroyuki
    Kanda, Junya
    Kobayashi, Masayuki
    Maeda, Takeshi
    Kitano, Toshiyuki
    Tsuji, Masaaki
    Ueda, Yasunori
    Ishikawa, Takayuki
    Nohgawa, Masaharu
    Watanabe, Mitsumasa
    Imada, Kazunori
    Moriguchi, Toshinori
    Itoh, Mitsuru
    Ohno, Hitoshi
    Yonezawa, Akihito
    Hirata, Hirokazu
    Arima, Nobuyoshi
    Asagoe, Kohsuke
    Anzai, Naoyuki
    Nagata, Kayoko
    Yasuno, Shinji
    Kuwabara, Yoshihiro
    Kitao, Hiromi
    Kim, Ihhwa
    Kawagishi, Kiyomi
    Ueshima, Kenji
    Tominari, Shinjiro
    Nakayama, Takeo
    Yamashita, Kouhei
    Takaori-Kondo, Akifumi
    [J]. HEMATOLOGY, 2022, 27 (01) : 239 - 248
  • [4] A Comparison of Cyclophosphamide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma
    Figueiredo, Amarilis
    Atkins, Harold
    Mallick, Ranjeeta
    Kekre, Natasha
    Kew, Andrea
    McCurdy, Arleigh
    [J]. BLOOD, 2016, 128 (22)
  • [5] Bortezomib-lenalidomide-dexamethasone versus bortezomib-cyclophosphamide-dexamethasone for newly diagnosed multiple myeloma patients eligible for autologous stem cell transplantation: A single center experience
    Kaloyannidis, P.
    Abduljalil, O.
    Abdulbaqi, M.
    Jatham, A.
    Estanislao, A.
    Raslan, H.
    Moinuddin, A.
    Apostolidis, J.
    Al Sagheir, A.
    Al Hashmi, H.
    Al Anazi, K.
    [J]. BONE MARROW TRANSPLANTATION, 2017, 52 : S462 - S462
  • [6] Bortezomib-Cyclophosphamide-Dexamethasone (VCD) versus Bortezomib-Thalidomide-Dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis
    Leiba, Merav
    Kedmi, Meirav
    Duek, Adrian
    Freidman, Tzachi
    Weiss, Mia
    Leiba, Ronit
    Nagler, Arnon
    Avigdor, Abraham
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2014, 166 (05) : 702 - 710
  • [7] Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma
    Reeder, Craig B.
    Reece, Donna E.
    Kukreti, Vishal
    Mikhael, Joseph R.
    Chen, Christine
    Trudel, Suzanne
    Laumann, Kristina
    Vohra, Harjot
    Fonseca, Rafael
    Bergsagel, P. Leif
    Leis, Jose F.
    Tiedemann, Rodger
    Stewart, A. Keith
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2014, 167 (04) : 563 - 565
  • [8] Dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed multiple myeloma
    Kropff, Martin
    Liebisch, Peter
    Wand, Hannes
    Weisel, Katja
    Gann, Claudia-Nanette
    Knop, Stefan
    Einsele, Hermann
    [J]. BLOOD, 2007, 110 (11) : 1053A - 1053A
  • [9] BORTEZOMIB-CYCLOPHOSPHAMIDE-DEXAMETHASONE AS INDUCTION THERAPY FOR TRASPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS IN A SPANISH CENTRE
    Sole, M.
    Zapata, R.
    Palma, A.
    Ruiz, M. A.
    Rodriguez, J. N.
    Dominguez, J. F.
    Gomez, K.
    Ramirez, S.
    [J]. HAEMATOLOGICA, 2018, 103 : 28 - 28
  • [10] Cyclophosphamide-bortezomib-dexamethasone compared with bortezomib-dexamethasone in transplantation-eligible patients with newly diagnosed multiple myeloma
    Figueiredo, A.
    Atkins, H.
    Mallick, R.
    Kekre, N.
    Kew, A.
    McCurdy, A.
    [J]. CURRENT ONCOLOGY, 2020, 27 (02) : E81 - E85
12345